EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity

Journal of Controlled Release

Volumn 157, Issue 2, 2012, Pages 287-296

  Sandoval, Michael A ^a   Sloat, Brian R ^a   Lansakara P , Dharmika S P ^a   Kumar, Amit ^a   Rodriguez, B Leticia ^a   Kiguchi, Kaoru ^a   Digiovanni, John ^a   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Biodistribution; Cytotoxicity; Ex vivo imaging; Particle uptake

Indexed keywords

ACTIVE TARGETING; ADENOCARCINOMA CELLS; ANTI-PROLIFERATIVE; ANTI-TUMOR ACTIVITIES; BIODISTRIBUTIONS; CELL LINES; EPIDERMAL GROWTH FACTOR RECEPTORS; EX VIVO IMAGING; FLUORESCENCE INTENSITIES; GEMCITABINE; HUMAN BREAST; HUMAN TUMORS; IN-VITRO; IN-VIVO; NANOPARTICLE FORMULATION; NATURAL LIGANDS; PARTICLE UPTAKE; TUMOR CELLS; TUMOR GROWTH;

CELL CULTURE; CELLS; CYTOTOXICITY; MAMMALS; NANOPARTICLES;

TUMORS;

4 (N) STEAROYL GEMCITABINE; ANTINEOPLASTIC AGENT; GEMCITABINE; NANOPARTICLE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TARGETING; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; ZETA POTENTIAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; OVALBUMIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN;

EID: 84855782779     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.08.015     Document Type: Article

References (38)

1. M. Barton-Burke Gemcitabine: a pharmacologic and clinical overview Cancer Nurs. 22 1999 176 183 (Pubitemid 29352696)
2. J.L. Arias, L.H. Reddy, and P. Couvreur Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine J. Drug Target. 17 2009 586 598
3. J.L. Arias, L.H. Reddy, and P. Couvreur Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system Biomacromolecules 12 2011 97 104
4. M. Celano, M.G. Calvagno, S. Bulotta, D. Paolino, F. Arturi, D. Rotiroti, S. Filetti, M. Fresta, and D. Russo Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells BMC Cancer 4 2004 63
5. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Control. Release 100 2004 331 346 (Pubitemid 39572916)
6. P. Jantscheff, V. Ziroli, N. Esser, R. Graeser, J. Kluth, A. Sukolinskaya, L.A. Taylor, C. Unger, and U. Massing Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model Clin. Exp. Metastasis 26 2009 981 992
7. D. Paolino, D. Cosco, L. Racanicchi, E. Trapasso, C. Celia, M. Iannone, E. Puxeddu, G. Costante, S. Filetti, D. Russo, and M. Fresta Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity J. Control. Release 144 2010 144 150
8. B.R. Sloat, M.A. Sandoval, D. Li, W.G. Chung, D.S.P. Lansakara-P., P.J. Proteau, K. Kiguchi, J. DiGiovanni, and Z. Cui In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharm. 409 2011 278 288
9. B. Stella, S. Arpicco, F. Rocco, V. Marsaud, J.M. Renoir, L. Cattel, and P. Couvreur Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules Int. J. Pharm. 344 2007 71 77 (Pubitemid 47464827)
10. C.X. Wang, L.S. Huang, L.B. Hou, L. Jiang, Z.T. Yan, Y.L. Wang, and Z.L. Chen Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model Brain Res. 1261 2009 91 99
11. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
12. C.F. LeMaistre, C. Meneghetti, L. Howes, and C.K. Osborne Targeting the EGF receptor in breast cancer treatment Breast Cancer Res. Treat. 32 1994 97 103 (Pubitemid 24322252)
13. J.G. Klijn, P.M. Berns, P.I. Schmitz, and J.A. Foekens The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients Endocr. Rev. 13 1992 3 17
14. J. Baselga Monoclonal antibodies directed at growth factor receptors Ann. Oncol. 11 Suppl. 3 2000 187 190
15. M. Ranson, L.A. Hammond, D. Ferry, M. Kris, A. Tullo, P.I. Murray, V. Miller, S. Averbuch, J. Ochs, C. Morris, A. Feyereislova, H. Swaisland, and E.K. Rowinsky ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J. Clin. Oncol. 20 2002 2240 2250 (Pubitemid 34441651)
16. F. Ciardiello, and G. Tortora Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs Eur. J. Cancer 39 2003 1348 1354 (Pubitemid 36773776)
17. E.B. Kullberg, M. Nestor, and L. Gedda Tumor-cell targeted epidermal growth factor liposomes loaded with boronated acridine: uptake and processing Pharm. Res. 20 2003 229 236 (Pubitemid 36269729)
18. C. Mamot, D.C. Drummond, U. Greiser, K. Hong, D.B. Kirpotin, J.D. Marks, and J.W. Park Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII- overexpressing tumor cells Cancer Res. 63 2003 3154 3161 (Pubitemid 36735867)
19. I.Y. Kim, Y.S. Kang, D.S. Lee, H.J. Park, E.K. Choi, Y.K. Oh, H.J. Son, and J.S. Kim Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice J. Control. Release 140 2009 55 60
20. G. Arya, M. Vandana, S. Acharya, and S.K. Sahoo Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy Nanomedicine 7 2011 859 870
21. R.M. Reilly, R. Kiarash, R.G. Cameron, N. Porlier, J. Sandhu, R.P. Hill, K. Vallis, A. Hendler, and J. Gariepy 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR J. Nucl. Med. 41 2000 429 438 (Pubitemid 30133961)
22. R.A. Walker, and S.J. Dearing Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas Breast Cancer Res. Treat. 53 1999 167 176 (Pubitemid 29161123)
23. B.R. Sloat, M.A. Sandoval, A.M. Hau, Y. He, and Z. Cui Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles J. Control. Release 141 2010 93 100
24. N. Yanasarn, B.R. Sloat, and Z. Cui Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel Int. J. Pharm. 379 2009 174 180
25. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 99 2010 306 314
26. A.R. French, D.K. Tadaki, S.K. Niyogi, and D.A. Lauffenburger Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction J. Biol. Chem. 270 1995 4334 4340
27. E. Spitzer, M. de Los Angeles, R. Perez, and R. Grosse Binding properties of biotinylated epidermal growth factor to its receptor on cultured cells and tissue sections J. Cell. Biochem. 41 1989 47 56 (Pubitemid 19277483)
28. G. Carpenter, and S. Cohen Epidermal growth factor Annu. Rev. Biochem. 48 1979 193 216 (Pubitemid 10191090)
29. K. Kurihara, S. Miyashita, G. Sazaki, T. Nakada, S.D. Durbin, H. Komatsu, T. Ohba, and K. Ohki Incorporation of impurity to a tetragonal lysozyme crystal J. Cryst. Growth 196 1999 285 290
30. T. Blessing, M. Kursa, R. Holzhauser, R. Kircheis, and E. Wagner Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery Bioconjug. Chem. 12 2001 529 537 (Pubitemid 32696226)
31. J. Gao, K. Chen, R. Xie, J. Xie, S. Lee, Z. Cheng, X. Peng, and X. Chen Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging Small 6 2010 256 261
32. G.E. Francis, C. Delgado, D. Fisher, F. Malik, and A.K. Agrawal Polyethylene glycol modification: relevance of improved methodology to tumour targeting J. Drug Target. 3 1996 321 340 (Pubitemid 26059823)
33. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740 (Pubitemid 44085631)
34. A. Wade, and P.J. Weller Handbook of Pharmaceutical Excipients 2nd Ed 1994 392 399
35. R.S. Herbst, and D.M. Shin Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy Cancer 94 2002 1593 1611 (Pubitemid 34212655)
36. M. Singh Transferrin as a targeting ligand for liposomes and anticancer drugs Curr. Pharm. Des. 5 1999 443 451 (Pubitemid 29319188)
37. Y. Zhang, and J. Zhang Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells J. Colloid Interface Sci. 283 2005 352 357 (Pubitemid 40254962)
38. A. Dienst, A. Grunow, M. Unruh, B. Rabausch, J.E. Nor, J.W. Fries, and C. Gottstein Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins J. Natl. Cancer Inst. 97 2005 733 747 (Pubitemid 40872380)